Seagen, Merck's Padcev-Keytruda combo snags FDA accelerated approval for bladder cancer
Seagen’s Padcev and Merck’s Keytruda have been cleared by the FDA as a combo for first-line treatment of bladder cancer, potentially …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
